Trimel to Report First Quarter 2013 Results and Host Investor Call

Posted: Published on May 3rd, 2013

This post was added by Dr P. Richardson

TORONTO, ONTARIO--(Marketwired - May 2, 2013) - Trimel Pharmaceuticals Corporation (TRL.TO) will report its first quarter financial results for the period ended March 31, 2013 on Wednesday, May 8, 2013 after the market closes.

Management of the Company will host a conference call to discuss these results and update investors on the status of its business on Thursday, May 9, 2013, at 8:30 a.m. Eastern Daylight Time.

To access the call live, please dial 416-340-2216 (Toronto), 1-866-226-1792 (Canada and U.S.) or 1- 800-9559-6849 (International). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7:00 p.m. Eastern Daylight Time on Thursday, May 16, 2013 by dialing 905-694-9451 (Toronto), 1-800-408-3053 (Canada and U.S.) or 00-800-3366-3052 (International), using access code: 3086288#.

For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at ir@trimelpharmaceuticals.com.

About Trimel

Trimel Pharmaceuticals Corporation (TRL.TO) - Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. A New Drug Application for CompleoTRT, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been filed with the FDA for regulatory approval in the United States. For more information, please visit http://www.trimelpharmaceuticals.com.

Read more from the original source:

Trimel to Report First Quarter 2013 Results and Host Investor Call

Related Posts
This entry was posted in Male Sexual Dysfunction. Bookmark the permalink.

Comments are closed.